ABSTRACT
OBJECTIVE Acromegaly is a rare neuroendocrine condition that can lead to significant morbidity; therefore, large studies are invaluable for understanding the disease burden. Despite China’s vast population size, studies on acromegaly remain sparse. In this report, we aimed to investigate clinical characteristics and predictors of biochemical remission after surgery for acromegaly.
METHODS A retrospective nationwide study was conducted using patient-reported data from the China Acromegaly Patient Association (CAPA) from 1998 to 2018. Univariate analyses were performed using Wilcoxon rank-sum tests, two-sample t-tests, and chi-squared tests. Using the purposeful selection method, multivariate logistic regression analysis was employed to determine independent predictors of biochemical remission at 3 months in patients after surgery.
RESULTS Of the 575 cases (mean age: 37.3 years; 59% female), macroadenomas and invasive tumors (Knosp score 3-4) were 87% and 61%, respectively. Ninety-five percent of patients were treated first with surgery (5.1% transcranial and 94.9% endonasal) and 38.3% exhibited biochemical remission at 3-months postoperatively. The following independent predictors of biochemical remission were identified: preoperative growth hormone (GH) levels between 12 and 28 μg/L [odds ratio (OR)=0.61; 95% confidence interval (CI), 0.39-0.96; p=0.031], preoperative GH levels >28 μg/L (OR=0.56; 95% CI, 0.35-0.90; p=0.016), macroadenoma (OR=0.57; 95% CI, 0.33-0.97; p=0.041), giant adenomas (OR=0.17; 95% CI, 0.06-0.44; p=0.0005), Knosp score 3-4 (OR=0.39; 95% CI, 0.25-0.59; p<0.0001), and preoperative medication usage (OR=2.16; 95% CI, 1.38-3.39; p=0.0008).
CONCLUSIONS In this nationwide study spanning over two decades, we highlight that higher preoperative GH levels, large tumor size, and greater extent of tumor invasiveness are associated with a lower likelihood of biochemical remission at 3-months after surgery, while preoperative medical therapy increases the chance of remission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the funding to SY through the Chinese Postdoctoral Science Foundation (2019M663271) and the Chinese Scholarship Council (201808440461), Guangzhou Science and Technology Project (201704020085) to HJW, and the National Institute of Health (NIH) Ruth L. Kirschstein National Research Service Award (T32DC000038-27) to LZ.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval (approved ID [2020] 091) for this retrospective study was obtained from CAPA and the institutional review board of The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: Leo Zekelman received funding from National Institute of Health (NIH) Ruth L. Kirschstein National Research Service Award (T32DC000038-27).
Financial support: This work was supported by the funding to SY through the Chinese Postdoctoral Science Foundation (2019M663271) and the Chinese Scholarship Council (201808440461), Guangzhou Science and Technology Project (201704020085) to HJW.
Data Availability
To protect the privacy of participated patients, the anonymized data not presented within this article will only be available upon request from any qualified investigators.
ABBREVIATIONS
- ACTH
- adrenocorticotropic hormone
- CAPA
- China Acromegaly Patient Association
- CI
- confidence interval
- CT
- computed tomography
- DA
- dopamine agonists
- FDR
- family discovery rate
- GH
- growth hormone
- ICA
- internal carotid artery
- IGF-1
- insulin-like growth factor 1
- LH
- luteinizing hormone
- IQR
- interquartile range
- MRI
- high-resolution magnetic resonance imaging
- OR
- odds ratio
- PRL
- prolactin (PRL)
- FSH
- follicle stimulating hormone
- TSH
- thyroid-stimulating hormone
- VIF
- variance influence factor
- SD
- standard deviation
- SRLs
- somatostatin receptor ligands
